QOP
SPRB

Quinn Opportunity Partners’s Spruce Biosciences SPRB Stock Holding History

Quinn Opportunity Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Hold
26,810
– – 0.07% 200
2026
Q1 		$1.75M Buy
26,810
+4,000
+18% +$276K 0.09% 173
2025
Q4 		$1.99M Buy
+22,810
New +$2.44M 0.08% 176

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Quinn Opportunity Partners's SPRB Position: Q2 2026 in Review

Quinn Opportunity Partners held its Spruce Biosciences (SPRB) position steady in Q2 2026 at 26,810 shares worth $1.45M. The position accounts for 0.07% of the portfolio, ranked #200.

Quinn Opportunity Partners first reported a position in SPRB in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.99M in Q4 2025. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Quinn Opportunity Partners held 26,810 shares of Spruce Biosciences worth $1.45M as of Q2 2026.
  • Quinn Opportunity Partners left its Spruce Biosciences share count unchanged in Q2 2026.
  • Spruce Biosciences made up 0.07% of Quinn Opportunity Partners's portfolio in Q2 2026, its #200 holding.
  • Quinn Opportunity Partners first reported a position in Spruce Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Quinn Opportunity Partners's Spruce Biosciences position peaked at $1.99M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.